readthroughSign in
Jun 30, 2026Trial update

Kymera registers long-term extension study for KT-621 in asthma patients

Kymera Therapeutics listed a Phase 2b open-label extension trial evaluating long-term safety of oral STAT6 degrader KT-621 in asthma.

Kymera Therapeutics had one registry update this week, a new extension trial building on its ongoing KT-621 asthma program.

  • KT-621, an oral STAT6 degrader, is being studied in "BREADTH-EXT" (NCT07677059), a Phase 2b open-label long-term extension trial for participants with asthma. This Phase 2b open-label, long-term extension study is designed to evaluate the long-term safety and efficacy of KT-621 in participants with asthma who were previously enrolled in the parent study (KT621-AS-202) of KT-621 for asthma.1 The study is recruiting, with an estimated enrollment of 264 participants (estimated)1 and an estimated start date of 2026-07 (estimated)1.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.